JGP Global Gestao de Recursos Ltda. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,053 shares of the medical research company’s stock after acquiring an additional 37 shares during the quarter. Thermo Fisher Scientific accounts for approximately 0.4% of JGP Global Gestao de Recursos Ltda.’s investment portfolio, making the stock its 25th largest holding. JGP Global Gestao de Recursos Ltda.’s holdings in Thermo Fisher Scientific were worth $992,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the stock. JJJ Advisors Inc. purchased a new position in Thermo Fisher Scientific in the third quarter valued at about $25,000. Ellevest Inc. boosted its holdings in shares of Thermo Fisher Scientific by 137.5% in the 2nd quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock valued at $28,000 after buying an additional 55 shares in the last quarter. American National Bank purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $29,000. Candriam Luxembourg S.C.A. grew its position in shares of Thermo Fisher Scientific by 11.3% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 104,069 shares of the medical research company’s stock worth $30,000 after buying an additional 10,569 shares during the last quarter. Finally, Corbenic Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 88.31% of the company’s stock.
Shares of NYSE TMO traded down $1.22 during mid-day trading on Friday, hitting $334.16. The stock had a trading volume of 626,533 shares, compared to its average volume of 866,984. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.23 and a current ratio of 1.80. The company has a 50 day moving average of $326.72 and a two-hundred day moving average of $299.56. Thermo Fisher Scientific Inc. has a twelve month low of $235.90 and a twelve month high of $342.26. The firm has a market cap of $136.36 billion, a PE ratio of 37.55, a PEG ratio of 2.00 and a beta of 1.12.
Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Friday, November 8th that permits the company to repurchase $2.50 million in shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th were paid a dividend of $0.19 per share. The ex-dividend date was Monday, December 16th. This represents a $0.76 annualized dividend and a yield of 0.23%. Thermo Fisher Scientific’s payout ratio is presently 6.83%.
TMO has been the subject of a number of analyst reports. Needham & Company LLC initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 3rd. They set a “strong-buy” rating and a $271.00 target price for the company. Evercore ISI upgraded shares of Thermo Fisher Scientific to an “outperform” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Wells Fargo & Co initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, January 7th. They set an “equal weight” rating and a $350.00 price target on the stock. Finally, Stifel Nicolaus started coverage on Thermo Fisher Scientific in a research report on Thursday, November 14th. They set a “buy” rating and a $345.00 price target on the stock. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $325.33.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: How to build a Fibonacci channel
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.